In order to provide such data, research in "behavioral psychopharmacology" must be a priority in military laboratories.
One technique of considerable military importance is use of sleeping aids to promote rapid sleep onset and permit efficient utilization of rest periods. Over the past four years, behavioral psychopharmacological research at the Naval Health Research Center (NHRC) has emphasized laboratory evaluation of sleeping aids for operational use.
The methodology devised to date in this research program is more generally applicable to the evaluation of all psychoactive drugs, including stimulants, and is potentially useful for testing the effects of toxic agents and/or antidotes.
To be suitable for use in operational settings, a sleeping aid must meet specific criteria:
1) It must be effective over the period of intended administration in reducing sleep latency and increasing sleep efficiency; 2) Adverse effects on performance must be absent or limited to a well-defined time @ • period post-administration; drug-induced alterations in arousability from sleep (such as elevation of auditory arousal threshold) or in memory functions (such as anterograde or retrograde amnesias) must be identified; 3) Development of tolerance and occurrence of withdrawal effects and side effects should be rare or nonexistent. The laboratory method for evaluation of sleeping Aids is described in this paper.
Our laboratory research has focused on two potentiaiiy suitable sleeping aids, the triazolobenzodiazepine triazolam (Halcion®) and the dietary amino acid, 1-tryptophan. Triazolam was of potential military interest because its short half-life, reported to be within the range of 2-3 hours, suggested that this drug might promote improved nighttime sleep without producing daytime performance impairment. In earlier studies, triazolam was demonstrated to be an effective hypnotic in doses ranging from 0.25-1.0 mg. There had been several previous studies which assessed morning performance following bedtime triazolam administration. The results of these studies differed, depending upon the dose size, schedule of performance testing, and type of performance task used. L-tryptophan, the amino acid, was studied because of previous reports of its more "natural" hypnotic effects.
In our initial evaluation of daytime hypnotic effects, 1-tryptophan 4 g reduced nap sleep latency by 46%. Its efficacy In daytime administration suggested its possible operational use in alleviating sleep problems due to jet lag or altered work-rest schedules. There had been little previous research on the effects of tryptophan on performance.
In laboratory study of triazolam 0.5 mg, sleep latency was reduced and morning performance was unimpaired, although a clear performance decrement was present up to 5 hours post-administration.
Triazolam also produced anterograde amnesia--that is, impairment of recall for stimuli presented during the effective phase of drug action--and elevated auditory threshold for arousal from sleep. This alteration of the sleeper's responsivity to auditory stimuli would act to maintain sleep in noisy environments, but it might also render the sleeper impervious to important auditory signals used in an operational environment. In operational use, triazolam could be effectively administered when rest periods of 8 hours duration are scheduled. However, based on our data, personnel would be more difficult to arouse from sleep, would perform less.effectively when awdkened, and would have mnemonic impairment up to 5 hours post-administration of triazolam.
In nighttime administration to chronic poor sleepers, 1-tryptophan 3 g reduced sleep latency after three nights of administration and had no adverse performance effects. The absence of performance effects is an important factor in the potential usefulness of I-tryptophan to the military. However, the late appearance of the hypnotics effects will require .urther evaluation.
In our earlier study assessing daytime hypnotic effectiveness in "good" and "average" sleepers, substantial sleep-inducing effects were present on the first day of administration. In the twelve night study, chronic "poor" sleepers were specifically chosen as subjects to provide a rigorous test of 1-tryptophan's hypnotic J%% effectiveness. The late hypnotic effects are probably a reflection of the difference between the daytime and nighttime studies in the type of subject recruited for participation. 
SLEEPING AIDS
The effects of sleep loss on human performance are well-documented. In operational settings, personnel must effectively utilize rest periods which may be brief and irreguLlarly scheduled. Because of the demands of military missions, It may be impossible to schedule sleep periods at biologically suitable times. Or, the nature of the mission may be such that personnel are on edge, aroused, or are "4
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In such situations, use of a carefully-selected sleeping aid may alleviate situationally-related sleep disturbances.
Elsewhere in these proceedings, some principles of sleep management in operational environments are presented by my colleague from NHRC, Dr. Paul Naitoh.
In order to develop a pharmacological sleep management technique, we have evaluated the suitability of various sleeping aids for use in operational settings.
1) It must be effective over the period of intended administration in reducing sleep latency and increasing sleep efficiency.
2) Adverse effects on performance must be absent or limited to a well-defined time period post-a~dministration; drug-induced alterations in arousibility from sleep (such as elevation of auditory arousal threshold) or in memory functions (such as anterograde or retrograde amnesias) must be identified.
3) Development of tolerance and occurrence of withdrawal effects and side effects should be rare or nonexistent.
While of substantial clinical value, the sedative-hypnotic flurazepam (Dalmane®) 30 mg was previously found to be inappropriate for operational use because of long-lasting adverse performance effects which persisted through the morning following bedtime administration [3] . More recently, our laboratory research has focused on two potentially suitable sleeping aids, the triazolobenzodiazepine triazolam (Halcion®) and the dietary amino acid, 1-tryptophan.
Triazolam
Various members of the class of benzodiazepine drugs are known to be effective hypnotics. Sleep laboratory studies of these agents have focused on measurement of the effects of these drugs on performance, as well as on assessment of their hypnotic efficacy. The triazolobenzodiazepine triazolam was of potential military interest because its short half-life, reported to be within the range of 2-3 hours, suggested that this drug might promote improved nighttime sleep without producing daytime performance impairment.
In earlier studies, triazolam was demonstrated to be an effective hypnotic in doses ranging from 0.25-1.0 mg [4] [5] [6] [7] [8] [9] [10] [11] [12] . There had been several previous studies which assessed morning performance following bedtime triazolam administration [5,8,10,13-151. The results of these studies differed, depending upon the dose size, schedule of performance testing, and type of performance task used. Acute effects of triazolam (0.25 mg and 0.5 mg) on performance were demonstrated at 3.5 hours post-administration in subjects who were awakened from sleep for performance testing [5] . Nicholson arid Stone [10] reported that visuo-motor performance was impaired up to 5 hours post-administration of 0.25 mg and 0.5 mg doses in daytime tests of subjects who remained awake.
L-tryptophan
The amino acid 1-tryptophan is regularly ingested in the diet as a constituent of protein foods.
L-tryptophan has been called a "natural hypnotic" [16, 17] . Plasma tryptophan levels, which show a diurnal rhythm with peak levels in the late evening hours, may be a physiological regulator of sleep onset.
In earlier sleep laboratory studies, 1-tryptophan was reported to significantly reduce sleep latency in doses ranging from 1-15 g [18] [19] [20] [21] [22] [23] [24] , but not all investigators have found sleep-facilitating effects [16, [25] [26] [27] [28] . Decreased time awake and/or increased total sleep time were found in some laboratory studies [16, [19] [20] [21] .
In awake subjects, early evening administration of 1-tryptophan (2 and 4 g) was demonstrated to increase subjective ratings of sleepiness on the Stanford Sleepiness Scale [29, 30] . In our initial evaluation of daytime hypnotic effects, we found that 1-tryptophan 4 g reduced nap sleep latency by 46% [31] . Its efficacy in daytime administration suggested its possible operational use in alleviating sleep problems due to jet lag or altered work-rest schedules. There had been little previous research on the effects of tryptophan on performance. Broadhurst [32] found that 1-tryptophan 2 g did not slow reaction time in test sessions conducted 2 hours post-administration.
Domino and Krause [33] reported that loading doses of tryptophan (32 mg/kg) produced a fairly rapid peak in plasma at 1.2 hours post-administration. Plasma half-life of total tryptophan was 2.7 hours.
These pharmacokinetic parameters indicated that any adverse performance effects associated with 1-tryptophan administration might be short-lived.
RESEARCH PROTOCOL
Triazolam 0.5 mg data were collected during the period 1978-1980. L-tryptophan 3 g ddta were collected during 1980-1982. The procedures for the two studies were identical.
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Subjects
Twenty male poor sleepers participated as subjects.
To qualify fcr participation, subjects had to identify themselves as "poor" sleepers, indicate a usual sleep latency of 45 minutes or longer, and report "trouble falling asleep" (i.e., sleep onset insomnia) for at least 6 months.
To meet the objective EEG criterion for participation, subjects had to exhibit sleep latencies (time from lights out to the onset of Stage 2 sleep) of 30 minutes or longer in the sleep laboratory on a screening night.
Procedure
A parallel, three-phase design was employed. Subjects who qual _d on the screening night went on to complete 11 additional nights of the 12-night protocol (Fig. 1 ). Following the screening night, subjects received placebos in a single-blind paradigm for 3 consecutive baseline nights. Following the placebo-baseline nights, 10 subjects received the active agent for 6 nights while the other 10 continued to receive placebo in a double-blind paradigm. After the 6 treatment nights, all subjects received placebo on 2 withdrawal nights.
12-NIG4T PROT=CI
Lights out was at 2200
and subjects were awakened at 0530. All-night sleep EEGs were recorded according to standard laboratory procedures. 
Performance during Awakenings from Sleep
On night 10, subjects were awakened from Stage 2 sleep during three preestablished time windows--90-100 minutes. 180-200 minutes, and 270-300 minutes after lights out--to complete performance tests. Performance testing generally occurred at times 1.5, 3, and 5 hours post-drug ingestion.
Following completion of each test battery, the subjects were instructed to go back to sleep. Latency of the return to sleep was recorded.
Memory
The effects of triazolam on retention of material learned prior to drug administration were evaluated through use of a paired associates (P-A) learning task. On study nights 2, 4, 5, 7, 9, 11, and 12, approximately 1 hour prior to drug administration, the subject learned 10 word pairs from a tape-recorded list. Morning P-A testing included recall and matching tasks. To check for anterograde amnesic effects, in the morning following night 10, subjects were presented with the Memory Checklist.
This list contained the 90 words which were presented in the Williams Word Memory Task during nighttime test sessions plus 90 filler words. Subjects were instructed to identify the words which had been -". .
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presented during the nighttime sessions.
Arousal Threshold Measures
The threshold for arousal from sleep was obtained on 3 recording nights: night 3
(placebo-baseline), night 6 (second treatment night), and night 8 (fourth treatment night). The subject's threshold for tones while awake was obtained prior to lights out. To obtain arousal thresholds, tones were begun at 20 dB above the awake threshold and were incremented in 5 dB steps until the subject made the behavioral (three button pushes) and verbal ("I'm awake") responses. Tones were 2 seconds long and occurred at 16-second intervals. Arousals were performed six times: #1: 
LABORATORY FINDINGS
The major findings regarding hypnotic efficacy and effects on performance and arousal threshold for triazolam and 1-tryptophan are described below. Only statistically significant effects are reported.
Triazolam
Triazolam significantly reduced sleep latency, and increased total sleep time and sleep efficiency. 
HO R O TD U i~~ -----
Triazolam subjects also had a significantly lower score (number correct) on the Memory Checklist in the morning following Night 10, indicating that anterograde amnesic effects were produced by triazolam administration. Performance on P-A recall and matching tasks were not altered by triazolam.
Compared to arousal threshold of placebo subjects, threshold for triazolam subjects was significantly higher during treatme.it at the time of the first, second, and third arousals (Fig. 4) .
Within the triazolam group, arousal threshold was significantly elevated during SWS. Over time, the placebo subjects appeared to become more sensitive to the tone and had significantly reduced arousal thresholds during the treatment. Latency of return to sleep following arousal by tones was '* significantly reduced for the first through third arousals in triazolam subjects. 
Based on our data, up to 5-hours post-administration, personnel would be more difficult to arouse from sloop, would pertorm less effectively when awake, and would have mnemonic impairment for information presented during this time period.
For 1-tryptophan, the absence of performance effects is an important factor in its potential usefulness to the military. However, the hypnotic efficacy of 1-tryptophan requires further discussion.
In our earlier study assessing its daytime effectiveness [31] , substantial sleep-inducing effects were present on the first day of administration.
In the 12-night study, hypnotic effects were not evident until the fourth night of administration. There were, in fact, three differences between the two studies: type of subject, dose size (3 versus 4 g), and time of day. All subjects in the nap S study reported being "average" or "good" sleepers, while, for the nighttime study, we specifically chose "poor" sleepers who had a persistent sleep onset problem, in order to provide a rigorous test of the efficacy of the sleeping aid.
Our results are compatible with the notion that there may be a biochemical correlate of chronic poor sleep which is gradually altered by 1-tryptophan treatment.
Alternatively, chronic poor sleepers may have a substantially different psychological "set" regarding sleep which Is psychologically and, ultimately, psychophysiologically incompatible with sleep onset.
The late hypnotic effects of 1-tryptophan in chronic poor sleepers may reflect the gradual dissolution of the psychological set to stay awake, mediated by repeated experience with the physiological deactivation produced by 1-tryptophan administration.
It is important to note, of course, that the subjects In the daytime study were theoretically in a physiological state incompatible with sleep onset, since they were asked to nap during their normal daytime working hours. The operationally-relevant question, as yet unanswered, is whether personnel in operational environments will respond to 1-tryptophan as normal sleepers trying to rest at odd and unusual times for sleep or as poor sleepers trying to sleep at normal bedtimes.
The issue of the adequacy of the 3 g dose is also of interest. It may be the case that a larger bedtime dose would have promoted sleep onset on the first night of administration in poor sleepers.
Schneider-Helmert [37] noted that in three studies of psychiatric patients with severe insomnia [16, 17, 38) , the effective dose range was 4-7.5 g, but the sleep-enhancing effects seen in these patients may have been more related to antidepressant effects of 1-tryptophan rather than to primary hypnotic effects. Brown et al. [23] found that 1-tryptophan 3 g reduced sleep latency on some but not all nights of administration in laboratory-screened Insomniacs. Hartmann et al. [21] have already shown that the dose-response curve for 1-tryptophan 1-15 g and sleep is "flat" for normal sleepers, although from Hartmann and Spinweher [24] , it is clear that the 1 g Is the smallest dose having hypnotic effects in normal sleepers. There are, thus, no strong data to suggest that a larger dose would have greater * hypnotic efficacy, although there is reason to suspect that there may be a smallest effective dose for .. various subject populations.
Finally, in consideration of the time of day difference between the two studies, we suggest that this factor is the least impressive and is, perhaps, the most counter-intuitive as an explanation for the differences in sleep latency between the two studies. 
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ABSTRACT (continued)
---decrement was present up to 5 hours post-administration. Triazolam also produced anterograde amnesia and elevated auditory threshold for arousal from sleep.. Ilh 'operational use, triazolam could be effectively administered when rest periods of 8 hours duration are scheduled. The dietary amino acid 1-tryptophan 4 g was effective in reducing daytime sleep latency in normal sleepers, suggesting its usefulness in alleviating sleep disturbances associated with jet lag and altered work-rest schedules.
In nighttime administration to chronic poor sleepers, 1-tryptophan 3 g reduced sleep latency after three nights of administration and had no adverse performance effects. The suitability of both triazolam and 1-tryptophan for military use will be further evaluated in field research and tested in operational environments. Another psychopharmacological approach is administration of carefully-chosen stimulants to maintain alertness and performance effectiveness when there is no opportunity for sleep. The techniques developed in this on-going research program in behavioral psychopharmacology will be employed to evaluate stimulants for operational use.
